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Jaroslaw Dziadeka
Institute of Medical Biology, Polish Academy of Sciences, Lodz, Polanda; Genome Damage and Stability Centre, University of Sussex, Falmer, Brighton, United Kingdomb;
Department of Immunoparasitology, University of Lodz, Lodz, Polandc
Mycobacteria contain genes for several DNA-dependent RNA primases, including dnaG, which encodes an essential replication
enzyme that has been proposed as a target for antituberculosis compounds. An in silico analysis revealed that mycobacteria also
possess archaeo-eukaryotic superfamily primases (AEPs) of unknown function. Using a homologous recombination system, we
obtained direct evidence that wild-type dnaG cannot be deleted from the chromosome ofMycobacterium smegmatiswithout
disrupting viability, even in backgrounds in which mycobacterial AEPs are overexpressed. In contrast, single-deletion AEPmu-
tants or mutants defective for all four identifiedM. smegmatis AEP genes did not exhibit growth defects under standard labora-
tory conditions. Deletion of native dnaG inM. smegmatiswas tolerated only after the integration of an extra intact copy of the
M. smegmatis orMycobacterium tuberculosis dnaG gene, under the control of chemically inducible promoters, into the attB site
of the chromosome.M. tuberculosis andM. smegmatisDnaG proteins were overproduced and purified, and their primase activi-
ties were confirmed using radioactive RNA synthesis assays. The enzymes appeared to be sensitive to known inhibitors (suramin
and doxorubicin) of DnaG. Notably,M. smegmatis bacilli appeared to be sensitive to doxorubicin and resistant to suramin. The
growth and survival of conditional mutant mycobacterial strains in which DnaG was significantly depleted were only slightly
affected under standard laboratory conditions. Thus, although DnaG is essential for mycobacterial viability, only low levels of
protein are required for growth. This suggests that very efficient inhibition of enzyme activity would be required for mycobacte-
rial DnaG to be useful as an antibiotic target.
Mycobacterium tuberculosis is a deadly pathogen that claimsnearly 2 million lives annually and infects an estimated 2
billion people, who serve as a reservoir of latently infected indi-
viduals (1). Most tuberculosis (TB) cases are not the result of new
infections but are caused by the reactivation of dormantM. tuber-
culosis (2). TB caused by drug-sensitive strains is fully treatable,
but patients must take three or four drugs for approximately 6
months. Premature termination of drug therapy results in the
emergence of resistant strains. The World Health Organization
estimates that 50 million individuals harbor multidrug-resistant
(MDR)M. tuberculosis, which is resistant to at least rifampin and
isoniazid. Treating these MDR strains requires second-line drugs,
which are expensive, have side effects, and take longer to work (up
to 2 years). More disturbing is that strains of untreatable exten-
sively drug-resistant (XDR)TB,which are additionally resistant to
any fluoroquinolone and at least one of three injectable second-
line drugs (capreomycin, kanamycin, or amikacin), have already
been identified in 58 countries. This XDR form, together with
totally drug-resistant (TDR) TB, seems to represent the greatest
health threat (3). The options for treating MDR/XDR/TDR TB
infections are becoming seriously limited, threatening to return
TB control to the preantibiotic era (4, 5). The first-line drugs for
treating TB are restricted to a few sensitive targets, including inhA
(NADH-dependent enoyl-[acyl carrier protein] reductase) and
kasA (3-oxoacyl-[acyl carrier protein] synthase 1) for isoniazid,
rpoB (DNA-directed RNA polymerase subunit beta) for rifampin,
and the embCAB operon for ethambutol. Also in this category are
enzymes required for the intracellular activation of currently used
drugs, such as katG (catalase peroxidase peroxynitritase T) for
isoniazid, pncA (pyrazinamidase/nicotinamidase) for pyrazin-
amide, and etaA (monooxygenase) for ethionamide (6). The iden-
tification of new drugs and sensitive targets would appear to be
indispensable for the control of drug-resistant forms of TB. One
requirement for a promising antibacterial enzyme target is that it
be essential for the organism and that it not be present in the host.
Such candidates might be found among basic essential metabo-
lism pathways, including DNA replication processes.
Bacterial DNA replication is performed by PolIII, which is un-
able to synthesize DNA de novo and therefore requires a primer to
allow the initiation of DNA synthesis. The replication of leading
strands requires at least a single primer to initiate the process, but
replication of the lagging strand requires an individual starter for
each Okazaki fragment. In Escherichia coli, the enzyme that syn-
thesizes such primers is the RNA polymerase, DnaG. Eukaryotes
also possess a distinct primase responsible for the synthesis of
RNA primers. DNA primase is a single-strand DNA (ssDNA)-
dependent RNApolymerase that plays a key role inDNA synthesis
(7). The DNA primases of bacteria and bacteriophages are classi-
fied into one group, and the primases of eukaryotes and archaea
belong to a second group. All primases sharemany catalytic prop-
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erties, but the proteins in the two classes differ both in structure
and in their relationship with other proteins in the replication
complex (8, 9). The prokaryotic primase associates with the rep-
licative DNA helicase. DnaG primase contains three distinct do-
mains, an N-terminal zinc-binding region, a middle RNA poly-
merase domain, and a C-terminal domain containing either a
DNA helicase (phage) or a region for interaction with the DNA
helicase (bacteria) (10). In contrast to DnaG primase, which is
monomeric, eukaryotic primase is a heterodimeric complex of
DNApolymerase and an accessory subunit. The small primase
subunit (PriS) belongs to the archaeo-eukaryotic primase (AEP)
superfamily (11). The PriS complex contains an active site for
RNA primer synthesis and the large primase accessory subunit
(PriL), whichmay coordinate primase and polymerase action and
is required for the initiation of primer synthesis (12). Previous
studies have demonstrated that AEPs are also present in diverse
bacteria (13, 14).
An AEP domain constitutes one of three domains in ATP-
dependent ligase (LigD), which is a key protein in the nonhomol-
ogous end-joining (NHEJ)DNA repair system (11, 15, 16, 17, 18).
The primase domain has terminal transferase, DNA-dependent
RNA primase, and DNA-dependent DNA/RNA gap-filling poly-
merase activities ( 15, 16, 18, 19, 20). Inmycobacteria, both DnaG
and AEPs have been reported. The replicative DnaG primase is
encoded by the dnaG gene, which is located in the dnaG operon
(21).
The viability of DnaGprimases as antibiotic targets rests on the
presumption that these enzymes are essential for all bacteria be-
cause they are required for initiatingDNA replication.However, it
is difficult to definitively establish this indispensability, which is a
fundamental prerequisite if these enzymes are to be considered
potential antibiotic targets. In this report, we undertook a series of
experiments that unequivocally demonstrate that dnaG is essen-
tial in Mycobacterium smegmatis, even in AEP-overexpressing
backgrounds.We also characterized the enzymatic activities ofM.
smegmatis and M. tuberculosis DnaG proteins. A detailed analysis
of the amount of DnaG in various strains revealed that the level of
protein can vary by6-fold without producing a major effect on
growth under standard laboratory conditions. Strains engineered
during this study will be useful in any future detailed evaluation of
antibiotics targeting DnaG.
MATERIALS AND METHODS
Bacterial strains and growth conditions. Strains used in this study were
derived from M. smegmatis mc2155 (22) and were cultured in Middle-
brook 7H9 broth supplemented with albumin-dextrose-sodium chloride
or NB broth (8.0 g/liter nutrient broth [Difco], 10.0 g/liter glucose).
Where required, further additions included 0.2% Tween 80 (pH 6.0 to
6.2), 50 g/ml hygromycin (Hyg), 7.5 g/ml gentamicin (Gen), and 25
g/ml kanamycin (Kan). Mycobacterial transformants were selected on
Middlebrook 7H10 agar plates enriched with albumin-dextrose-sodium
chloride containing Kan (25g/ml), Gen (7.5g/ml), orHyg (50g/ml).
E. coli strains were cultured in LB medium (10 g/liter tryptone, 5 g/liter
yeast extract, 10 g/liter NaCl, pH 7.0). Where required, further additions
included 100g/ml ampicillin (Amp), 200g/mlHyg, and 50g/mlKan.
Gene-cloning strategies. Standard molecular biology methods were
used for all cloning protocols (23). All PCR products were obtained using
thermostable AccuPrime Pfx DNA polymerase (Invitrogen), cloned ini-
tially into a blunt vector (pJet1.2; Fermentas), sequenced, and then re-
leased by digestion with the appropriate restriction enzymes before clon-
ing into the final vectors. Subcloning into expression vectors was
facilitated by incorporating restriction enzyme recognition sites into the
sequence of the primers. The plasmids used in this work are listed in Table
S1 in the supplemental material.
Construction of gene-replacement vectors. To perform unmarked
deletions of dnaG, prim2, prim3, and prim4 genes in M. smegmatis, we
used a suicidal recombination delivery vector based on p2NIL (24). The
recombination vector carried the 5= end of dnaGwith the upstream region
connected to the 3= end of the genewith the downstream region, amplified
with the primers shown in Table S2 in the supplemental material. The
aacC1 gene was then introduced between the upstream and downstream
regions of dnaG. Finally, the PacI screening cassette from pGOAL17 was
inserted into the constructs, resulting in the suicide delivery vectors
pMK165, pAB148, pMK189, and pMK190 carrying dnaG::aacC1R,
prim2, prim3, and prim4, respectively; these were used to engineer
the directed M. smegmatis mutants as described previously (25, 26). The
resultant mutant strains were verified by PCR and Southern blot hybrid-
ization (see Fig. S1 in the supplemental material).
Construction of complementation plasmids. M. smegmatis genes
(dnaG, ligD, prim2, prim3, prim4), M. tuberculosis dnaG, and E. coli dnaG
were amplified by PCR using the primers listed in Table S2 in the supple-
mental material and cloned into the BamHI-XbaI sites of the pJam2 vec-
tor downstream from the Pami promoter (see Table S2). Next, all genes
with their Pami promoters were excised from these vectors with HindIII
and XbaI and cloned into the integration vector pMV306, generating
pMK172, pMK207, pAB145, pMK206, pMK193, pMK173, and pMK174
for dnaG, ligD, prim2, prim3, prim4 (M. smegmatis), dnaG (M. tuberculo-
sis), and dnaG (E. coli), respectively. The M. smegmatis dnaG gene was
amplified by PCR using the primers listed in Table S2 and cloned into the
BamHI-HindIII sites of the pKW08Lx vector downstream from the Ptet
promoter (see Table S2). Next, genes with their Ptet promoters were ex-
cised from this vector (pMK214) with HindIII and XbaI and cloned into
the integration vector pKW08Lx-Int, generating the pMK215 vector.
Disruption ofM. smegmatis genes encoding primases. The protocol
of Parish and Stoker (24) was used to disrupt the M. smegmatis dnaG
prim2, prim3, prim4, and ligD genes at their native loci on the chromo-
some. The mutants were generated by subsequent disruption of individ-
ual genes. The suicidal recombination plasmid DNA (pMK165, pAB148,
pMK189, pMK190, and pMK111) was treated with NaOH (0.2 mM) and
integrated into the M. smegmatis mc2155 chromosome by homologous
recombination. The resulting single-crossover recombinant (SCO) mu-
tant colonies were blue, resistant to Kan andGen, and sensitive to sucrose.
The site of recombination was confirmed by PCR and Southern hybrid-
ization. The SCO strainswere further processed to select for double-cross-
over (DCO) mutants that were white, sensitive to Kan, and resistant to
sucrose (2%). PCR and Southern hybridization analyses were used to
distinguish between the wild type and each mutant DCO. Probes that
hybridized to each gene, labeled using a nonradioactive primer extension
system (DIG-labeling system; Amersham, GE Healthcare, Sweden), were
generated by PCR. The primers used for PCR amplification are listed in
Table S2 in the supplemental material.
Protein purification. For protein expression, all E. coli cultures were
grown at 37°C in LBmedium containing Amp. The expression constructs
were made by PCR amplification ofM. smegmatis dnaG (dnaGMs) andM.
tuberculosis dnaG (dnaGMtb), cloning into pJet1.2, excising with BamHI/
HindIII (for dnaGMs) or BamHI/EcoRI (for dnaGMtb), and cloning into
the final vectors, pHIS and pGEX, respectively. The pHIS and pGEX de-
rivatives were transformed into E. coli BL21(DE3), and cells were plated
on LB agar containing antibiotics and grown overnight. Single colonies
were inoculated into 5 ml liquid medium, grown overnight, and diluted
100-fold into fresh medium (500 ml). After the colonies were grown to
midexponential phase (optical density at 600 nm [OD600], 0.8 to 1.0),
protein expression was induced by the addition of IPTG (isopropyl -D-
1-thiogalactopyranoside) to 0.4 mM. After overnight incubation, cells
were harvested, sonicated, and centrifuged to separate the soluble and
insoluble fractions. DnaG DNA primase was purified from the soluble
Kuron et al.
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fraction by affinity column chromatography using Ni2-charged His
Bind resin (Novagen) for the His-tagged protein and glutathione agarose
(Pierce) for the glutathione S-transferase (GST)-tagged protein. After
concentration of protein using Amicon Ultra 4-ml concentrators with a
30,000molecular-weight cut-off polyethersulfone (PES)membrane, pro-
tein sample concentrations were determined using the bicinchoninic acid
(BCA)method (Bio-Radprotein assay). The purifiedDnaGandLigD (15)
were used for rabbit immunization as described previously (26).
DnaG primase activity assay. In vitro assays of primase activity were
performed essentially as described previously (27). The reaction mixture
(total volume, 25 l) for the RNA primer synthesis assays contained 50
mMHEPES (pH 7.5), 100 mM potassium glutamate, 10 mM dithiothre-
itol, 10 mM magnesium acetate (or 10 mM manganese chloride), and 2
M ssDNA template (5=-tactctcatcgtggaatcctgaca). DnaG primase was
added to a final concentration of 3 M, and the sample was preincubated
for 10 min at 30°C. After the addition of ATP, CTP, GTP (each to a final
concentration of 200 M), UTP (to a final concentration of 20 M), and
0.6 Ci of [-32P]UTP (3,000 Ci/nmol), the sample was incubated for an
additional 4 h. The reaction was stopped by adding 30 l of 3 M sodium
acetate. The RNA products were then precipitated overnight at 70°C
with 96% cold ethanol in the presence of 40g glycogen. The precipitates
were washed with 75% cold ethanol and dissolved in 8 l loading buffer
(95% formaldehyde, 0.05% bromophenol blue, 0.05% xylene cyanol, 20
mM EDTA). Samples were heated at 98°C for 10 min, and the reaction
products were separated by electrophoresis in 18% urea-polyacrylamide
gel. After electrophoresis, the results were visualized by autoradiography
using X-ray film with intensifying screens overnight at70°C. The sensi-
tivity of DnaG to inhibitors (suramin and doxorubicin) relative to the
controls was determined by adding an inhibitor to the reaction buffer at
concentrations ranging from 1 to 100 M.
AlamarBlue and CFU susceptibility tests. The microplate alamar-
Blue assay (28) was used to test the sensitivity of mycobacteria to DnaG
inhibitors. Suramin and doxorubicin were dissolved in NB medium at
final concentrations of 0.039 to 5mM(suramin) or 0.98 to 125M(doxo-
rubicin), filtered (0.22 m), and distributed in the wells of microtiter
plates (100 l/well). Next, 100 l of wild-typeM. smegmatis and comple-
mented dnaG mutants (OD600, 0.1) was added to the control wells and
to thewells containing inhibitors. The plateswere incubated at 37°C for 72
h in a humidified atmosphere. AlamarBlue reagent (25 l; Invitrogen)
was added, and the plates were incubated overnight at 37°C. A color
change from blue to pink indicated bacterial growth. The MIC was de-
fined as the lowest drug concentration that prevented a color change. The
sensitivity of mycobacteria to suramin and doxorubicin was also deter-
mined by monitoring the numbers of CFU of the wild-type and mutant
strains growing in the presence of different concentration of inhibitors as
described previously (29).
RNAextraction and reverse transcription. For quantitative real-time
PCR (qRT-PCR) experiments with prim2, prim3, and prim4 transcripts,
RNA was extracted from wild-type M. smegmatis strains and from the
SCO strains (dnaG::aacC1-dnaG) carrying an extra copy of an AEP gene
under the control of a chemically inducible promoter (attB::Pamiprim2/
prim3/prim4) using the TRIzol LS reagent (Invitrogen) as described pre-
viously (26). For reverse transcription, we used a SuperScript III first-
strand synthesis system (Invitrogen) and performed the reactions in total
volumes of 20 l containing 1 g of total RNA. Subsequently, 2 l of
cDNA (equivalent to 50 ng of RNA) was used in the qRT-PCR experi-
ments (see below).
qRT-PCR. qRT-PCR for the analysis of prim2, prim3, and prim4 gene
expressions was performed using the Maxima SYBR green qPCR master
mix (Fermentas) and a 7900HT real-time PCR system (Applied Biosys-
tems). Each reaction mixture (final volume, 25 l) was mixed on ice and
contained 1	Maxima SYBR green qPCRmastermix, 50 ng of cDNA, and
0.3Meach primer (see Table S2 in the supplemental material for primer
sequences). For expression analysis of theM. smegmatis prim2, prim3, and
prim4 genes, we used a three-step cycling protocol in which the reaction
mixtures were first heated to 95°C for 10 min and were then subjected to
45 cycles at 95°C for 15 s (denaturation), at 63°C for 30 s (annealing), and
at 72°C for 30 s (extension). The data were acquired during the extension
step. To verify the specificities and identities of the PCR products gener-
ated, melting curve analysis was performed at the end of each PCR. Each
experiment was performed in triplicate, and the results are presented as
the means and standard errors. The results were normalized with respect
to sigA gene expression as the internal control and reflect the fold change
in the expression of a given gene in the mutant strain versus the wild-type
strain, as calculated using the double-delta method 2-CT (30).
RESULTS
Rv2343c andMsmeg4482 genes encode active primases that are
sensitive to doxorubicin and suramin. Bacterial primases
(DnaG) are highly conserved across all bacterial genomes, allow-
ing ready identification of homologous genes by bioinformatics
analysis. The DnaG ofM. tuberculosis displays 48% similarity and
32% identity with its E. coli counterpart and as much as 89%
similarity and 82% identity with the DnaG of M. smegmatis (see
http://www.ncbi.nlm.nih.gov/blast/Blast.cgi). In contrast, bacte-
rial primases are distinct from their eukaryotic and archaeal coun-
terparts, which makes them an attractive antibacterial drug target
(31, 32). The genomes of fast- and slow-growing mycobacteria
each carry a single gene that is homologous to bacterial dnaG
(Msmeg4482 and Rv2343c for fast and slow growers, respec-
tively). The activity of M. tuberculosis DnaG was recently con-
firmed in an in vitro study (32). We used a pT7 Pol-based E. coli
expression system to overproduce and purify DnaG from M.
smegmatis and M. tuberculosis, and we subsequently used the pu-
rified DnaG of M. smegmatis for the vaccination of a rabbit to
obtain polyclonal antibodies. The primase activities of DnaGs
from these two strains were monitored by visualizing and quanti-
fying radiolabeled RNA primer products on denaturing gels. We
tested a number of templates and reaction parameters to identify
the optimal conditions for DnaG activity. A reaction buffer sup-
plemented with Mn2 or Mg2 and a 24-mer (5=-tactctcatcgtgga
atcctgaca) ssDNA template allowed us to confirm the activity of
both enzymes (Fig. 1). DnaG activity was suppressed in the pres-
ence of doxorubicin (100 M) and suramin (10 M), known
inhibitors of DnaG (32), which inhibited the activities ofM. smeg-
matis and M. tuberculosis DnaG in vitro by about 85% and 70%,
respectively (Fig. 2A). Notably, doxorubicin, but not suramin,
displayed antibacterial activity againstM. smegmatis grown in liq-
uid culture. The alamarBlue assay, which allowed us to monitor
cell viability, showed that 8 M doxorubicin inhibits the growth
ofmycobacteria.On the other hand, suraminwas tolerated even at
concentrations of 5mM(see Fig. S2 in the supplementalmaterial).
The CFU analysis of M. smegmatis growing in the presence of
different concentrations of doxorubicin revealed dose-dependent
inhibition of growth (Fig. 2B). Moreover, the M. smegmatis mu-
tant expressing as little as about 20% of the physiological level of
DnaG appeared to bemore sensitive to doxorubicin than thewild-
type strain (Fig. 2C). In the presence of 2.5 M and 3 M doxo-
rubicin, the numbers of viable cells were at 50% and 20%, respec-
tively, of those viable in the wild-type culture.
The activity of DnaG, but not that of primases in the AEP
family, is essential for M. smegmatis viability. Bioinformatic
analyses of the genomes of M. tuberculosis and M. smegmatis
showed that, in addition to dnaG, mycobacteria also contain pu-
tative AEP-like primase genes. The best characterized of these is
PolDom, an AEP that is part of a multidomain enzyme called
DnaG as a Putative Target for New Tuberculostatics
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ligase D (LigD), which is required for NHEJ DNA repair during
the stationary phase (15, 19). The function of other genes display-
ing homology toAEPs remains to be elucidated. Similar to the case
in other bacteria, the dnaG gene of M. smegmatis was previously
reported to be essential for viability (21). Here, we used a gene-
replacement strategy to verify that dnaG is essential in mycobac-
teria and tested whether AEPs are also essential. In contrast
to dnaG, which could not be replaced by a nonfunctional copy
without disrupting viability, individual or collective removal of
intact AEP genes in M. smegmatis to generate MSMEG_
5570, MSMEG_6301, MSMEG_0597, MSMEG_2105 or
(MSMEG_5570; MSMEG_6301; MSMEG_0597; MSMEG_
2105) was well tolerated, establishing that the AEPs are not essen-
tial for the viability ofM. smegmatis (see Fig. S1 in the supplemen-
tal material). To further confirm that dnaG is essential and to
engineer a dnaG conditional mutant, we cloned the intact gene
into a plasmid that placed it under the control of a tetracycline- or
acetamide-inducible promoter (Ptet/Pami) and introduced this
construct into the attB locus ofM. smegmatis chromosomal DNA.
The additional dnaG copy enabled us to replace the native dnaG
gene with its mutated copy. The genotype of each mutant was
confirmed by Southern blotting hybridization (Fig. 3). Addition-
ally, the attB integrated, intact copy of dnaG provided with
pMV306Hygr vector was subjected for replacement with an
“empty” pMV306Kanr vector in six independent experiments.
The lack of Kanr recombinants without an intact dnaG confirmed
additionally the essentiality of DnaG for viability ofM. smegmatis
(33).
DnaG is not complemented by AEPs. Since the only essential
primase in mycobacteria is DnaG, it can be considered essential
for replication of chromosomal DNA. To evaluate DnaG as a po-
tential drug target, we tested whether it is still essential in an AEP-
overexpressing background. Genes encoding AEPs were cloned to
place them under the control of a chemically inducible promoter
(Pami) and integrated into the attB locus of anM. smegmatis SCO
mutant carrying both a functional dnaG gene and a dnaG gene
disrupted by the aacC1R gene (dnaG::aacC1R). The overexpres-
sion of AEPs was confirmed by Western blot analysis (LigD) or
quantitative RT-PCR (prim2, prim3, and prim4) (see Fig. S3 in the
supplemental material). Next, we selected for mutants lacking an
intact copy of dnaG (i.e., those carrying dnaG::aacC1R exclu-
sively). In no case did the overexpression of AEPs rescue the via-
bility defect ofM. smegmatis lacking an intact chromosomal dnaG
gene, confirming that dnaG is essential and demonstrating that
these primases serve nonredundant functions. Next, we tested
whether M. smegmatis dnaG could be replaced by its counterpart
from M. tuberculosis or E. coli. The introduction of PamidnaGMtb
into the attB locus allowed us to remove the native dnaG gene
without disrupting viability (Fig. 3). Removal of the native copy of
dnaG from M. smegmatis chromosomal DNA was not tolerated
following introduction of E. coli dnaG (PamidnaGEc) into the attB
site ofM. smegmatis SCO strain, suggesting that themycobacterial
DnaG have distinct activities or interactions that are essential for
replication in these organisms.
Depletion of DnaG only modestly affects the viability of M.
smegmatis. The depletion of an ideal drug target should result in
bacterial cell death or at least in the inhibition of growth. Having
confirmed that DnaG is essential for the viability of mycobacteria,
even in AEP overproduction backgrounds, we sought to test the
effect of controlled DnaG depletion on the viability of M. smeg-
FIG 1 The purification and activity ofM. smegmatis (Ms) andM. tuberculosis (Mtb) DnaG proteins. (A) SDS-PAGE analysis. Purified proteins were resolved on
a 12%polyacrylamide gel followed by Instant Blue staining.Mw,molecular weight; nt, nucleotides. (B)Western blot analysis with antibodies raised against DnaG
of M. smegmatis. (C) Protein activity assays with Mg2, as described in Materials and Methods.
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matis. To this end,we grew a conditionalDnaG expressionmutant
carrying only intact dnaGMs (or dnaGMtb) under the control of a
chemically inducible Ptet promoter (or Pami), with and without
anhydrotetracycline (or acetamide) as an inducer. The growth of
the wild-type control strain and conditional mutants was moni-
tored by measuring the optical density at 600 nm (OD600) and
determining colony formation; the DnaG protein level was mon-
itored by Western blotting (Fig. 4). Surprisingly, an approxi-
mately 83% reduction of DnaG protein levels inM. smegmatis did
not (according to the OD600) or only modestly (0.5 to 0.8 log in
CFU) affected the growth of bacterial cultures, suggesting that
mycobacteria can tolerate substantial depletion of this protein, an
observation that has important implications for evaluations of
DnaG as a future drug target. The growth inhibition effect was not
observed whenmineral mediumwas used to culture wild-typeM.
smegmatis or conditional mutants (data not shown).
DISCUSSION
The ability to replicate DNA is essential for the viability of every
living organism. Consequently, the proteins involved in replica-
tion should be essential for viability, at least as long as other pro-
teins cannot complement their functions. Some antibiotics (e.g.,
doxorubicin, suramin) are known to interfere with the replication
machinery of bacteria; however, neither first-line anti-TB drugs
nor second-line anti-TB drugs target the mycobacterial replisome
(6). We previously evaluated NAD-dependent DNA ligase
(LigA), which appeared to be essential for mycobacterial viability,
as a putative drug target (34). LigA inhibitors that do not affect
ATP-dependent ligases were also identified (35, 36). Unexpect-
edly, depletion of LigA did not significantly affect the growth of
mycobacteria (34), largely precluding LigA as a target for new
anti-TB drugs. Recently, Biswas et al. developed a colorimetric
primase-phosphatase assay as a tool for screening for efficient
DnaG inhibitors (32). These researchers used this assay to screen
2,556 small molecules and identified suramin, doxorubicin, and
ellagic acid as potential DnaG inhibitors. Here, we evaluated
DnaG from mycobacteria as a drug target and engineered an M.
smegmatis strain carrying only intact M. tuberculosis dnaG under
the control of a chemically inducible promoter. As previously re-
FIG 2 (A) Synthesis of radiolabeled RNA primers by M. smegmatis DnaG and its inhibition by doxorubicin and suramin. Phosphorimager analysis of an 18%
urea–polyacrylamide gel showing RNA products of the priming reaction. The priming reaction was performed with Mn2 on a 24-mer ssDNA template
(5=-tactctcatcgtggaatcctgaca) in the presence of amixture of the four nucleotides containing [-32P]UTP. (B) Time-dependent colony formation bywild-typeM.
smegmatis (M. smegmatis mc2155) growing in the presence of various concentrations of doxorubicin (0, 2, 2.5, and 3 M). Colony formation values are
means
 standard errors from three independent experiments. (C) The dose-dependent colony formation by wild-type M. smegmatis (M. smegmatis mc2155)
and its mutant with downregulated DnaG expression (dnaGPtetdnaG) growing in the presence of doxorubicin. The number of CFU of 24-h-old culture is
shown. Colony formation values are means
 standard errors from three independent experiments.
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ported (21), dnaG appeared to be essential for the viability of M.
smegmatis. The genomes of bothM. tuberculosis andM. smegmatis
containmultiple copies of a second class ofDNAprimases belong-
ing to the AEP family. However, we found that DnaG is still essen-
tial, even in strains that overexpress these AEP enzymes, establish-
ing that they cannot complement the priming activity of DnaG.
The overexpressions of AEPs were confirmed at the protein
(LigD) or RNA (Prim2, Prim3, and Prim4) level, and we are not
able to exclude the possibility that, in the latter case, some troubles
at the translation step occurred. Conversely, the overexpressing
genes were originally from the same strain, and common prob-
lems (e.g., different GC content, codon usage) for heterogeneous
protein expression should not have a place. In contrast to DnaG,
individual or even all AEPs were inactivated without affecting the
growth ofM. smegmatismutants. This observation would suggest
that AEPs identified in mycobacteria do not participate in DNA
replication and more likely have other roles, including DNA re-
pair.
DnaGs of M. smegmatis and M. tuberculosis were expressed in
E. coli and purified to near homogeneity for biochemical studies.
The two enzymes were shown to possess primase activity in the
presence of Mn2 and ssDNA (24-mer) that was significantly in-
hibited in the presence of suramin or doxorubicin. However, only
doxorubicin appeared to inhibit the growth of wild-typeM. smeg-
matis and a dnaGM. smegmatismutant carrying an intact dnaG
from M. smegmatis. The observed resistance to a high concentra-
tion of suraminmight reflect the limited ability of this compound
to permeate mycobacterial cell walls, which are well known for
presenting a permeability barrier for hydrophobic and hydro-
philic compounds (37, 38). The efficiency of a given inhibitor as
an antibacterial drug depends on the intracellular ratio of inhibi-
tor to its target. Thus, the concentration of target protein and the
minimal concentration required to reduce cell viability are deter-
minants of the success of treatment. In cases where bacilli are
highly sensitive to reductions in the concentration of a givenmol-
ecule, the molecule in question is a promising drug target. Myco-
bacterial DnaG may not satisfy this criterion because as little as
17% of wild-type DnaG levels appeared to be sufficient to support
the growth ofM. smegmatis; thus, DnaGmay not be a good target
for potential anti-TB drugs. As noted above, we observed a similar
FIG 3 Complementation of theM. smegmatis dnaG SCO strain. (A) Schematic showing the restriction-digested DNA fragment (1,862 bp) and the size of the
internal deletion in the mutated gene (1,180 bp). The dnaG gene is represented by gray arrows and the internal deletion by white rectangles. The aacC1 gene
(gentamicin resistance cassette) was cloned within the dnaG gene to facilitate screening of DCOmutants. The dnaG is essential for the viability ofM. smegmatis.
SCO strains were enriched with intact dnaG from M. smegmatis or M. tuberculosis under the control of an inducible promoter (PamidnaGMs/dnaGMt or
PtetdnaGMs). (B) The genotype of selected strains was confirmed by PCR and Southern hybridization analysis.
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effect for mycobacterial LigA, another essential replication pro-
tein (34). This might suggest that replication proteins are overex-
pressed in mycobacteria under normal growth conditions, possi-
bly owing to their relatively slow doubling times (39). It has also
been reported that 1 to 3% of LigA is sufficient to support E. coli
growth under laboratory conditions (40, 41). It is not clear why
bacteria express “extra” replication proteins, but it may be related
to additional functions performed by these proteins in the cell.
The extensive use of LigA or DnaG in DNA damage and repair/
recombination pathways might dictate that cells produce a much
larger amount of these proteins. The overcapacity in terms of the
amount of DnaG available in M. smegmatis suggests that an irre-
versible inhibitor would be required to eliminate DnaG activity.
This likely inhibitory requirement should be taken into account
during the screening of new chemicals to target this and related
essential replication-associated proteins. The high level of identity
betweenM. smegmatis andM. tuberculosisDnaG and the comple-
mentation of M. smegmatis dnaG by intact dnaGMtb without a
detectable effect on viability or the growth rate suggest that our
findings are not limited to nonpathogenic mycobacteria. Thus, a
fast-growing nonpathogenic strain expressing DnaG from M. tu-
berculosis would appear to be very useful for the initial testing of
DnaG inhibitors identified by random in vitro screening or
through rational drug design. Unlike LigA, mycobacterial DnaG
was not replaced with its E. coli counterpart. This is consistent
with the limited identity between M. smegmatis and E. coli DnaG
(32%), which might preclude the interaction of E. coliDnaG with
themycobacterial replisome. The evaluation ofDnaGas a putative
drug target and construction ofM. smegmatis conditionalmutants
should help in future studies to identify chemicals that efficiently
target this essential replication protein in mycobacteria.
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